Interestingly, both studies described therapy de-escalation considerably more often than escalation, presumably reflecting both differences in the patient population as well as in the willingness to recommend adjuvant chemotherapy in intermediate-risk HR-positive, HER2-negative early breast cancer. Here, ERBB2 is linked to breast carcinoma.